These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23835926)

  • 1. Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy.
    Ravanelli M; Farina D; Morassi M; Roca E; Cavalleri G; Tassi G; Maroldi R
    Eur Radiol; 2013 Dec; 23(12):3450-5. PubMed ID: 23835926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer.
    Fried DV; Tucker SL; Zhou S; Liao Z; Mawlawi O; Ibbott G; Court LE
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):834-42. PubMed ID: 25220716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple preoperative computed tomography image analysis shows good predictive performance for pathological vessel invasion in clinical stage IA non-small cell lung cancer.
    Ito T; Murakawa T; Sato H; Tanabe A; Maekawa M; Yoshida Y; Fukayama M; Nakajima J
    Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):633-8. PubMed ID: 22740516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.
    Wu YC; Hsu HH; Chang WC; Tung HJ; Ko KH; Hsu YC; Huang TW; Ho CL; Chang H
    Eur Radiol; 2015 Jun; 25(6):1801-13. PubMed ID: 25577523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma.
    Hong SR; Hur J; Moon YW; Han K; Chang S; Kim JY; Im DJ; Suh YJ; Hong YJ; Lee HJ; Kim YJ; Choi BW
    Eur J Radiol; 2018 Apr; 101():118-123. PubMed ID: 29571784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer.
    Yoshida Y; Murayama T; Sato Y; Suzuki Y; Saito H; Nomura Y
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):507-14. PubMed ID: 26366891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage.
    Ganeshan B; Abaleke S; Young RC; Chatwin CR; Miles KA
    Cancer Imaging; 2010 Jul; 10(1):137-43. PubMed ID: 20605762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
    J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
    Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M
    Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.